Spyre Therapeutics stock dips premarket after Friday surge as $500 million shelf hangs over shares
Spyre Therapeutics dropped 4.2% to $41.38 in premarket action Monday, after its last trade came in at $43.21.
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus
Spyre Therapeutics, Inc. shares fell 6.6% on Friday to $30.58, finishing the first U.S. trading day of 2026 near the lower end of the session’s $30.11-$33.31 range. The stock remains below its 52-week high of $34.49 after trading about 889,000 shares, while biotech benchmarks were little changed.